Adenocarcinoma of Endometrium
Understanding Adenocarcinoma of Endometrium (Endometrial Cancer, Uterine Cancer) diagnosis? Find clear information on Endometrial Cancer staging, ICD-10 codes for Uterine Cancer, SNOMED CT codes for Adenocarcinoma of Endometrium, and healthcare documentation best practices for Adenocarcinoma of the Endometrium. This resource supports accurate clinical documentation and medical coding for optimal patient care.
Cancer originating in the uterine lining (endometrium).
Abnormal vaginal bleeding, pelvic pain, postmenopausal bleeding.
Gynecology, oncology, primary care.
ICD-10 Code Families
Complete code families applicable to C54.1
When to use each related code
| Description | When to use |
|---|---|
| Cancer of the uterine lining. | Use for malignant tumors of the endometrium. Includes subtypes like endometrioid and serous. |
| Precancerous changes in the uterine lining. | Use for endometrial hyperplasia, including atypical hyperplasia, a precursor to endometrial cancer. |
| Benign smooth muscle tumor of the uterus. | Use for uterine fibroids (leiomyomas), common benign tumors affecting the uterine muscle. |
Best-practice checklist
- ✓Adenocarcinoma of endometrium diagnosis: Document grade.
- ✓Endometrial cancer: Laterality, size, location.
- ✓Uterine cancer: Myometrial invasion depth.
- ✓Endometrial cancer staging: FIGO stage required.
- ✓Uterine cancer: Lymph node involvement documented.
Common pitfalls to avoid
Incorrect coding of adenocarcinoma subtypes or differentiation (e.g., endometrioid, serous) impacting staging and treatment.
Inaccurate documentation of myometrial invasion depth affecting stage and subsequent treatment planning.
Missing documentation specifying laterality (if applicable) for bilateral or unilateral involvement, impacting staging.
Best-practice tips
- 01Code C54.1 for primary endometrial adenocarcinoma, Z85.42 for personal history.
- 02Document tumor grade, stage, and size for accurate risk stratification.
- 03Abstract staging data from pathology reports for precise coding.
- 04Ensure complete documentation of hormonal therapies and treatments.
- 05Regularly audit endometrial cancer cases for coding and CDI compliance.
Step-by-step checklist
- 1
Verify endometrial sampling (biopsy/D&C) confirms adenocarcinoma.
- 2
Review imaging (ultrasound/MRI pelvis) for myometrial invasion/spread.
- 3
Assess CA-125 levels pre-op for risk stratification.
- 4
Document tumor grade, stage (FIGO), and histology for accurate coding (ICD-10 C54.x).
- 5
Confirm patient understands treatment plan and prognosis (shared decision-making).
Ready-to-paste narrative
Patient presents with complaints consistent with possible endometrial adenocarcinoma, including abnormal uterine bleeding, postmenopausal bleeding, and pelvic pain. A comprehensive review of systems was conducted, noting relevant symptoms such as fatigue, weight loss, and abdominal bloating. Past medical history includes hypertension and obesity. Family history is significant for breast cancer in her mother. Physical examination revealed an enlarged uterus. Transvaginal ultrasound demonstrates endometrial thickening, prompting further evaluation. Endometrial biopsy was performed and pathology report confirms the diagnosis of adenocarcinoma of the endometrium, also referred to as uterine cancer. Differential diagnoses considered included endometrial hyperplasia, uterine fibroids, and endometrial polyps. Staging workup, including pelvic MRI and CT scan of the abdomen and pelvis, is planned to assess for metastatic disease. The patient was counseled regarding treatment options for endometrial cancer, including hysterectomy, radiation therapy, chemotherapy, and hormone therapy. Risks and benefits of each treatment modality were discussed. The patient will be referred to a gynecologic oncologist for further management and treatment planning. This case of endometrial carcinoma requires careful consideration of the patient's age, overall health, and the stage of the cancer to determine the most appropriate course of action. Follow-up appointments are scheduled for ongoing monitoring and surveillance. ICD-10 code C54.1 is recorded for malignant neoplasm of corpus uteri.
Common questions and answers
What are the most effective current treatment strategies for stage III endometrial adenocarcinoma, considering molecular classification?+
Treatment for stage III endometrial adenocarcinoma is complex and requires a multidisciplinary approach tailored to the individual patient's molecular classification. Current National Comprehensive Cancer Network (NCCN) guidelines recommend surgery (total hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy) as the cornerstone of treatment for most patients. Adjuvant therapy is frequently indicated and determined by molecular subtype, stage, and grade. For example, patients with high-risk features (e.g., serous or clear cell histology, lymphovascular space invasion) or advanced stage often benefit from adjuvant chemotherapy with carboplatin and paclitaxel. Molecular profiling, including assessment of mismatch repair (MMR) status, p53, and POLE mutation status, is essential for guiding treatment decisions. Patients with MMR-deficient tumors may benefit from immunotherapy with pembrolizumab. Consider implementing molecular testing into your clinical practice to personalize treatment strategies for optimal outcomes. Explore how S10.AI can help streamline molecular testing workflows and provide insights for personalized cancer care.
How can I accurately differentiate between type I and type II endometrial adenocarcinoma in my clinical practice, and what are the key implications for prognosis and management?+
Distinguishing between type I and type II endometrial adenocarcinoma is crucial for appropriate management. Type I, typically endometrioid histology, is associated with estrogen excess, often arises from atypical endometrial hyperplasia, and generally has a favorable prognosis. Conversely, type II tumors, including serous, clear cell, and undifferentiated carcinomas, are less common, are not associated with estrogen, and tend to be more aggressive with a poorer prognosis. Histopathological evaluation remains the gold standard for diagnosis, but certain clinical features can raise suspicion. Type I tumors often present with postmenopausal bleeding and are associated with obesity and diabetes. Type II tumors may present with abnormal vaginal discharge or pelvic pain and are less strongly associated with these risk factors. Accurate diagnosis relies on careful histopathological review, including immunohistochemistry. Given the differences in prognosis and treatment, ensuring accurate subtyping is crucial for personalized management. Learn more about how S10.AI can assist in clinical decision support for endometrial cancer by providing evidence-based insights.
What are the best practices for post-treatment surveillance and follow-up care for patients with endometrial adenocarcinoma to ensure early detection of recurrence and optimize long-term outcomes?+
Post-treatment surveillance for endometrial adenocarcinoma focuses on early detection of recurrence and management of long-term treatment-related side effects. The NCCN guidelines provide recommendations for surveillance frequency and modalities based on stage and risk factors. Typically, this includes regular pelvic exams, CA-125 measurements, and imaging studies (e.g., CT scans, chest x-rays) at defined intervals. The frequency and intensity of surveillance are tailored to the individual patient's risk profile. For patients with early-stage disease, less intensive surveillance may be appropriate, while those with high-risk features or advanced stage require more frequent monitoring. Patient education and support are essential components of post-treatment care, addressing potential long-term physical and psychological effects of treatment. Consider implementing a structured survivorship care plan to optimize long-term outcomes and quality of life for your patients. Explore how S10.AI can assist in automating patient follow-up and generating personalized survivorship care plans.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.